Coulter Partners Top hires for Q2-2025

28th July 2025 Source: Top Hires Bulletin

Copied link to clipboard!

In the second quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.

We successfully placed executives for venture capital & private equity-backed firms, alongside large-cap, mid-cap, and public companies, filling critical roles across diverse disciplines worldwide.

CEO/ C-suite/ Board

CEO, ADC oncology company (VC-backed), UK
CEO, Immuno-oncology therapeutics (Publicly listed), US
CEO, Sustainable chemical biomanufacturing (VC-backed), Sweden
CEO, Exosome technologies (VC-backed), Italy
Chief Commercial Officer, Cell therapy biotech (Publicly listed), US
Chief Business Officer/ Chief Financial Officer, Epigenetics (VC-backed), US
Chief Financial Officer, Small molecule therapeutics (VC-backed), US
Chair, Healthtech (VC-backed), US
Board Director, Specialized healthcare manufacturing (Publicly listed), Australia
Board Director, Obesity therapeutics (Publicly listed), US
Board Director, Oncology therapeutics (VC-backed), Australia
Board Director, Antibody platform technologies (VC-backed), Canada

Commercial/Functional/Strategic

VP, Sales & Marketing Europe, Surgical technologies (Privately owned), Germany
VP, Strategy (Diagnostics), Genetic testing (Publicly listed), US
VP, Global Marketing, CDMO (Large operating subsidiary), US
Country Chief Financial Officer, Healthcare services (PE-backed), Germany
General Manager, Europe, Cell therapy biotech (Publicly listed), US
General Manager & Alliance Lead, International Markets, Biopharmaceuticals (Publicly listed), US
Global IT Director, Specialty pharma (Family owned), Italy
Corporate HR Director, Hormonal health (Family owned), France
Senior Director, Commercial Operations, Medical devices (Publicly listed), Netherlands

R&D/Medical/Technical

Chief Scientific Officer, AI-enabled CNS therapeutics (VC-backed), US
Chief Technology Officer, Neuromodulation devices (VC-backed), UK
VP, Head Translational Development, Genomic technologies (VC-backed), Spain
VP, Combination Product Quality & Safety, Multinational biotech (Publicly listed), US
AVP, Technical Operations, Life-extending technologies (Publicly listed), US
Head Clinical Safety, Specialty pharma (Privately owned), France
Global Head Toxicology Services, Laboratory & consulting services (PE-backed), Germany
Global Medical Affairs Director/s, Medical apparatus leader (Publicly listed), France

Investor/ Not for Profit/ Accelerator/ Other

Senior General Partner, Science & research VC, Germany
Venture Partner, Life sciences investor, Denmark
Investment Professional, Life sciences investor, US
Director of Venture Creation, Leading university, UK